Navigation Links
Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find
Date:4/14/2008

(PHILADELPHIA) Researchers at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia are inching closer to understanding how common blood pressure medications might help prevent the spread of pancreatic cancer. They have found in the laboratory that one type of pressure-lowering drug called an angiotensin receptor blocker inhibits pancreatic cancer cell growth and causes cell death.

In earlier work in the laboratory, Hwyda Arafat, M.D., Ph.D., associate professor of Surgery at Jefferson Medical College, and her team showed that angiotensin receptor blockers may help reduce the development of tumor-feeding blood vessels, a process called angiogenesis. Other studies have linked a lower incidence of cancer with the use of angiotensin blocking therapies. Such drugs, she says, may become part of a novel strategy to control the growth and spread of cancer.

One of these drugs AT1R (Ang II type 1 receptor) blockers inhibit the function of the hormone angiotensin II (Ang II) in the pancreas. The receptor is expressed in pancreatic cancer cells. Ang II increases the production of VEGF, a vascular factor that promotes blood vessel growth in a number of cancers. High VEGF levels have been correlated with poor cancer prognosis and early recurrence after surgery. Dr. Arafats research team has shown that AngII indirectly causes VEGF expression by increasing AT1R expression.

Dr. Arafats group explored the effects of blocking AT1R on the pancreatic cancer cell reproductive cycle and programmed cell death, or apoptosis, and the mechanisms involved. It found that blocking AT1R inhibited pancreatic cancer cell growth and promoted cell death. This happens through inducing the activity of the gene p53, which controls programmed cell death, and also by inhibiting anti-cell death pathways such as those involving the gene bcl-2. The team reports its findings April 14, 2008 at the annual meeting of the American Association for Cancer Research in San Diego.

The researchers also found that blocking AT1R affects p21, a gene that regulates the cell cycle. We found that blocking this receptor can cause cell cycle arrest, she notes.

This is really exciting because the role of this receptor has never been known, Dr. Arafat says. Its never been connected to cell division or apoptosis. Were also now further exploring the mechanisms involved. The exciting thing is that this receptor already has so many available pharmaceutical blockers on the market. Ultimately, the group hopes to be able to test these agents in human trials, she says.


'/>"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
2. PATHFAST(R): Rapid Whole Blood Immunoassay Analyzer from Polymedco
3. Blood vessels: The pied piper for growing nerve cells
4. Cholesterol, blood pressure control may reverse atherosclerosis in adults with diabetes
5. Aggressive Cholesterol, Blood Pressure Treatment Shows Some Benefit
6. Microwave treatments for enlarged prostate cause blood pressure surges
7. Blood pressure enzyme can have tumor-sensing role
8. Stem cell research leads to potential new therapy for rare blood disorder
9. Gator Blood May Be New Source of Antibiotics
10. Leaky blood vessels open up nerve cells to toxic assault in Lou Gehrigs disease
11. Tight Backpack Straps Cut Blood to Shoulders, Arms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... ... a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed ... top students from U.S. universities who will draw from Siemens’ deep knowledge ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... members of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on ...
(Date:2/12/2016)... Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn from ... will show what to expect when they come knocking this year. But that takes time. ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , ... of pharmaceutical products, garnering increased attention from all stakeholders in the development of ...
(Date:2/12/2016)... ... 12, 2016 , ... Each year, the American Physical Therapy Association (APTA) offers ... the Anaheim Convention Center. Almost 10,000 physical therapists across the country are expected to ... more about their chosen field and network with their colleagues. As in years ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016   National Community Pharmacists Association ... MBA issued the following statement today in response to ... the Centers for Medicare & Medicaid Services (CMS) ... beneficiary advocates and others: patient advocacy organizations ... still reviewing the full CMS analysis. Our initial reaction ...
(Date:2/12/2016)... ALEXANDRIA, Va. , Feb. 12, 2016  This ... & Specialty Pharmacy (JMCP) takes an in-depth look ... the recent spike in prescription drug spending, which has ... JMCP Editor-in-Chief Laura E. Happe ... Laura E. Happe , PharmD, MPH. --> ...
(Date:2/12/2016)... , Feb. 12, 2016 Hypermarcas S.A. ... cash tender offer (the "Tender Offer") to purchase ... aggregate principal amount of its 6.500% Senior Notes ... Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In connection with ... "Consent Solicitation") consents (the "Consents") of the holders ...
Breaking Medicine Technology: